Elevate Bio, a new biotechnology holding company, has begun its operations in Cambridge, Massachusetts, it was reported yesterday.
The organisation's aim is to develop a portfolio of cell and gene therapy companies by partnering with top academic researchers, medical centres and entrepreneurs.
The company is supported by USD150m funding raised through a Series A financing round co-led by the MPM Capital-managed UBS Oncology Impact Fund and F2 Ventures. Other investors in the company include EcoR1 Capital, Redmile Group, and Samsara BioCapital. Its business model is structured to build single- and multi-product cell and gene therapy companies by providing scientific founders with centralised bench-to-bedside capabilities such as world-class scientists, drug development and commercialisation expertise, and manufacturing facilities among others.
The firm has founded a single research and development, process development and cGMP manufacturing subsidiary called ElevateBio BaseCamp.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories